Bioconjugates: The Adaptable Challenge - Conjugation of a biologic to a carrier molecule can solve problems in solubility and stability, but introduces its own set of challenges. - BioPharm

ADVERTISEMENT

Bioconjugates: The Adaptable Challenge
Conjugation of a biologic to a carrier molecule can solve problems in solubility and stability, but introduces its own set of challenges.


BioPharm International
Volume 26, Issue 1, pp. 34-38

THE ADAPTABLE CHALLENGE

Bioconjugates are versatile and can be used for a number of different applications. Most importantly, they are being used for extending the half-life of the peptide. Despite their many uses they face a number of challenges. Depending on the type of conjugate, there may be safety issues with their toxicological profile as is the case with PEGs. In the case of polypeptide-based conjugates, there is concern over immunogenicity. Economic hurdles, although not a major concern at early stages of development, are certainly a concern at larger scale and at later stages of clinical development of the bioconjugates. The ability to purchase these conjugates from several sources is important for risk mitigation. The analytical hurdles encountered with bioconjugates are of paramount concern, especially with regulatory bodies. Advances in linker technology or analytical methods are vital to deal with these analytical challenges. Bioconjugates are the adaptable challenge.

ACKNOWLEDGMENTS

The author would like to thank the colleagues who provided ideas and comments during preparation of this paper. The author would also like to provide special thanks to Dr. Sheri Barrack, PhD, for her support, information and guidance during preparation of this article. Dr. Barrack is the senior vice-president of pharmaceutical development for Cebix, Inc.

Trishul Shah is the business development key account manager for the PolyPeptide Group, North America, Torrance, CA.
.

REFERENCES

1. Pharma Exec News, "PEGylation: Advantages And Potential," Apr. 7, 2009, http://www.pharmaexecnews.com/biotechnology/pegylation-advantages-potential accessed Aug. 10, 2012.

2. J.M. Harris and R.B. Chess, Nature Rev. Drug Discov. 2, 214–221 (2003).

3. P. Taupin et al., "PEG and PEG Conjugates Toxicity: Towards an Understanding of the Toxicity of PEG and its Relevance to PEGylated Biologicals," in PEGylated Protein Drugs: Basic Science and Clinical Applications (Birkhäuser Verlag, Basel, Switzerland, 2009), pp. 127–146.

4. Peptide Therapeutics Foundation, Peptide Therapeutics Foundation Database 2010.

5. F.M. Veronese, Biomaterials 22, 405–417 (2001).

6. J.M. Harris, M.D. Bentley, and M.J. Roberts, Adv. Drug Deliv. Rev. 54, 459–476 (2002).


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

GPhA Issues Statement on Generic Drug Costs
November 20, 2014
Amgen Opens Single-Use Manufacturing Plant in Singapore
November 20, 2014
Manufacturing Issues Crucial to Combating Ebola
November 20, 2014
FDA Requests Comments on Generic Drug Submission Criteria
November 20, 2014
USP Joins Chinese Pharmacopoeia Commission for Annual Science Meeting
November 20, 2014
Author Guidelines
Source: BioPharm International,
Click here